BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CGT6297 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CGT6297\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07383506-9142@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:CGT6297: Phase 1 readout est. (NCT07383506)
DESCRIPTION:CGT6297\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Study of Mutant Selective-Inhibitor (CGT6297)\, in Patients With Advanc
 ed Solid Tumors\nEstimated primary completion: July 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cgt6297#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07383506
URL:https://assetmemo.bio/drug/cgt6297#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
